Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9. (December 2022)

• Record Type: Journal Article
• Authors: Leung, Alex K.K.; Xue, Yuan Chao; de Guzman, Antyrah; Grzelkovski, Guilherme; Kong, HyeJin Julia; Genga, Kelly R.; Russell, James A.; Boyd, John H.; Francis, Gordon A.; Walley, Keith R.
• Is Part Of: Atherosclerosis. Volume 362(2022)
• Page Start: 29
• Page End: 37
• Publication Date: 2022-12
• Subjects: Endothelial cells -- Inflammation -- Lipopolysaccharide -- Proprotein convertase subtilisin-kexin type 9; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2022.09.008
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and Aims: Endotoxins carried within LDL are cleared from the circulation via hepatic LDL receptor (LDLR)-mediated endocytosis. Proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces this clearance by down-regulating LDLR density on hepatocytes. In addition to hepatocytes, vascular endothelial cells also express receptor targets of PCSK9, including LDLR. Therefore, we hypothesized that PCSK9 may regulate vascular endothelial cell uptake of lipopolysaccharide (LPS) and alter the vascular endothelial cell inflammatory response. Methods and results: We found that LPS is internalized by human umbilical vein vascular endothelial cells (HUVECs) and LPS uptake dose-dependently increased with increasing LDL concentration. Intracellular LPS co-localized with LDL. PCSK9 and, separately, blocking antibodies against LDLR, dose-dependently decreased the vascular endothelial cell uptake of LPS and, furthermore, inhibition of endocytosis using Dynasore blocked LPS uptake. In contrast, blocking antibodies against TLR4 did not alter LPS uptake. PCSK9 decreased the LPS-induced proinflammatory response (IL-6 and IL-8 gene expression and protein secretion, and VCAM-1/ICAM-1 expression) in vascular endothelial cells. In addition, a decrease in PCSK9 and increase in LDLR, mediated by triciribine or siPCSK9, increased LPS uptake and the LPS-induced proinflammatory response. Similar results were also found in aortic vascular tissue from Pcsk9 −/− mice after LPS injection. Conclusions: Our data suggest that, similar to PCSK9 treatment in hepatocytes, PCSK9 reduces vascular endothelial cell uptake of LPS via LDLR-mediated endocytosis. Consequently, PCSK9 decreases the LPS-induced proinflammatory response in vascular endothelial cells. These results raise the possibility that PCSK9 inhibition may have additional effects on vascular endothelial inflammation via this alternative pathway, beyond the known effects of PCSK9 inhibition on LDL lowering and hepatic endotoxin clearance. Graphical abstract: Image 1 Highlights: Lipopolysaccharide (LPS) uptake in HUVECs is dose-dependent on LDL concentration. PCSK9 dose-dependently inhibits LDLR-mediated endocytosis of LPS in HUVECs. Decreased PCSK9 increases endothelial cell LPS uptake and proinflammatory response.